Page 4 - Pharma Sector

ECDS to set up medical equipment manufacturing unit with ₹780 cr investment

ECDS, a company specialised in sustainable development technologies, on Wednesday announced it will set up a medical equipment manufacturing unit in Ujjain with an initial investment of Rs 780 crore under a joint venture with three South Korean companies. According to the company, this will be its first factory in India. "We have submitted a proposal to the state government to set up a unit on 15.60 acres of land in the Medical Equipment Park in Vikram Udyogpuri, Ujjain, of which we have already acquired 1.5 acres. This will be our first unit in the country," said Rajesh Bharadwaj, director of ECDS's Indian branch. He said construction will begin this year with an initial investment of Rs 780 crore, and the first phase of production will start by April 2027. "In the first phase, efforts will be made to provide employment to approximately 500 people," Bharadwaj told reporters in Indore. He said ECDS has partnered with three South Korean companies in a 50:50 joint venture to impleme

JM Financial flags growth concerns in Mankind Pharma; initiates with Reduce

JM Financial raised concerns around Mankind Pharma's recent BSV acquisition, which was executed at a high valuation and is expected to dilute return on capital

Budget announcements to position India as value-led biopharma ecosystem

Pharma-focused Budget 2026 measures could help India move beyond generics by boosting biologics, biosimilars, regulatory capacity and early-stage innovation, analysts say

US market remained a drag for Indian pharma in Q3 amid pricing pressure

The US market stayed a weak spot for Indian pharma companies in Q3FY26 amid sustained pricing pressure in generics, heightened competition and product-specific challenges

India-US trade deal: Pharma sees no major change during Section 232 probe

India's pharmaceutical exports to the US are unlikely to see major tariff changes under the interim pact as Section 232 investigations continue, though medical devices may gain from better access

Alembic to skip first wave of global semaglutide launches, eyes India

Alembic Pharmaceuticals said it will miss the first wave of global generic semaglutide launches but is exploring partnerships for a faster entry into the Indian market

Emcure Q3 results: PAT jumps 48% as India, overseas revenues surge

Pune-based Emcure Pharma posted strong Q3 FY26 results on double-digit domestic and international growth, as it eyes entry into India's top 10 drugmakers

Tariff reset lifts India's medical device pulse amid China+1 shift

US tariff cut lifts Indian medical devices; pharma steady, nutraceuticals seek clarity

Mankind Pharma Q3 PAT up 9.5%, revenue rises 11.5% on chronic drugs sales

Mankind Pharma posted a 9.5 per cent rise in Q3FY26 net profit and 11.5 per cent growth in revenue, driven by strong domestic demand for chronic therapies

Budget 2026: Pharma dept prescribes PLI boost for bulk drug output

FY27 PLI scheme allocation rises 2.24%, aiming to add 500 MT to domestic API production

Union Budget 2026-27: Over ₹1 trillion earmarked for the nation's health

Biopharma Shakti initiative to tackle burden of non-communicable diseases, turn India into global, innovation-led hub

Budget 2026: Towards a healthier India through strategic healthcare push

The Budget reframes healthcare as a strategic national capability, backing biopharma innovation, workforce expansion and technology-led governance to power India's next growth phase

Budget 2026: Biopharma Shakti plan aims to make India a biologics hub

Union Budget 2026: Finance Minister Nirmala Sitharaman unveils Biopharma Shakti, a ₹10,000 crore, five-year plan to boost domestic biologics, biosimilars, clinical trials and regulatory capacity

FM announces ₹10,000 crore scheme to promote biopharma manufacturing

Finance Minister Nirmala Sitharaman announced Mission Biopharma Shakti in the Budget, a five-year ₹10,000 crore programme to build domestic capabilities in biologics, biosimilars and clinical research

Centre proposes amendment to allow drug imports via Navi Mumbai airport

Health Ministry proposes listing Navi Mumbai International Airport as a notified port under drug rules, enabling air import of medicines through the facility

Sun Pharma Q3 Preview: Profit, revenue and key factors to watch in Dec qtr

Sun Pharma's net profit is expected to come at ₹3,040 crore, marking a decline of 5.6 per cent Y-o-Y, as against ₹3,220 crore in the year-ago period

India-EU free trade pact set to redraw growth map for Indian CDMOs

India-EU FTA could transform India's CDMO sector by cutting pharma tariffs, easing regulations and deepening Indian integration into Europe's drug supply chains

India-EU FTA: Brokerages decode impact for markets, sectors, companies

In fiscal 2024-25 (FY25), India, according to HSBC, exported $76 billion worth of goods to the EU and bought $61 billion worth of goods from the EU

Centre puts stricter controls on pregabalin sales over abuse concerns

India has moved pregabalin to Schedule H1, tightening prescription and record-keeping norms after states flagged widespread misuse of the nerve pain drug for intoxication

Centre scraps prior approval system for BA/BE studies of low-risk drugs

The health ministry has amended clinical trial rules to replace prior approvals for low-risk BA/BE studies with simple online intimations, a move aimed at cutting delays, easing compliance